J&J's Doxil manufacturer, Ben Venue, halts production
This article was originally published in Scrip
Executive Summary
Ben Venue, an Ohio-based CMO and Boehringer Ingelheim subsidiary, is temporarily halting production and distribution, citing overdue preventative maintenance and requalification of some equipment. The measure will compound global shortages of J&J's anti-cancer Doxil/Caelyx (doxorubicin HCl liposome injection) which is manufactured at the plant.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.